Ortin Global Ltd (ORTINGLOBE.BO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR m | 82 | 82 | 60 | - | - | - | 44 | - |
| Operating profit | INR m | 3 | -4 | ||||||
| Net profit | INR m | 9 | -4 | -1 | - | - | - | -8 | - |
| EPS reported | INR | -0.12 | -1.02 | ||||||
| Operating cashflow per share | INR | -0.80 | -1.12 | ||||||
| Capex per share | INR | 0.00 | 0.00 | ||||||
| FCF per share | INR | -0.80 | -1.13 | ||||||
| Free cash flow | INR m | -6 | - | ||||||
| Net debt | INR m | 62 | 57 | ||||||
| Book value equity | INR m | 109 | 98 | ||||||
| Book value per share | INR | 13.36 | 12.00 | ||||||
| Number of shares | m | 8.13 | 8.13 | ||||||
| DPS (TTM paid) | INR | 0.00 | 0.00 |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.69 | 10.44 | ||||||
| P/S LTM | x | 3.06 | 168.46 | ||||||
| P/FCF LTM | x | -28.29 | -14.12 | ||||||
| EV/EBITDA LTM | x | 45.95 | -14.93 | ||||||
| EV/Sales LTM | x | 3.39 | 173.66 | ||||||
| Earnings Yield LTM | % | -0.66% | -6.99% | ||||||
| FCF Yield | % | -3.54% | -7.08% | ||||||
| Quality | |||||||||
| ROE | % | -0.86% | -62.12% | ||||||
| ROIC | % | +1.29% | -52.04% | ||||||
| Operating margin | % | +4.51% | -15.21% | ||||||
| Gross margin | % | +22.08% | -1.40% | ||||||
| FCF/Sales | % | -10.83% | -1193.09% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -27.10% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +8.39% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.10 | - | ||||||
| Net Debt/EBITDA | x | 11.89 | -0.45 | ||||||
| EBIT/Net interest | x | 0.69 | -507.26 | ||||||
| Net debt/market cap | % | +45.59% | +7.78% | ||||||
| Net debt/Equity | x | 0.57 | 0.58 | ||||||
| Gross debt/equity | x | 0.59 | 0.62 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ortin Global Ltd (ORTINGLOBE.BO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free